Bremelanotide Improves Sexual Desire in Premenopausal Women: Patient Experiences Revealed

Hypoactive Sexual Desire Disorder (HSDD) is a common and distressing condition characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant personal distress. It affects a substantial number of premenopausal women, impacting their quality of life and relationships. While Bremelanotide (marketed as Vyleesi) has been approved as an on-demand treatment for HSDD, there remains a critical need to understand the real-world patient experience, satisfaction, and perceived efficacy from those who have used it in a clinical setting.

The study revealed overwhelmingly positive patient experiences, with a significant proportion of women reporting meaningful improvements in their sexual desire and associated distress. Specifically, 78% of participants reported an improvement in their sexual desire, and 65% experienced a reduction in distress related to low sexual desire. The mean FSFI desire domain score increased by 2.2 points (p<0.001) from baseline, indicating a statistically significant enhancement in sexual desire. The most impactful finding was that 82% of women expressed overall satisfaction with Bremelanotide treatment, leading to a 2.4-fold increase in reported sexual satisfaction compared to their pre-treatment state. While common side effects like transient nausea (45%) and flushing (28%) were reported, 92% of patients found these adverse events tolerable, with only 4% discontinuing treatment due to side effects. Furthermore, 70% of women indicated they would recommend Bremelanotide to other women experiencing HSDD.